COMPOUND FOR TREATING CANCER CAUSED BY CELLS EXPRESSING MELANOTRANSFERRIN AT THEIR SURFACE

The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compos...

Full description

Saved in:
Bibliographic Details
Main Authors DEMEULE, MICHEL, ROLLAND, YANNÈVE, BERTRAND, YANICK, MICHAUD-LEVESQUE, JONATHAN, BELIVEAU, RICHARD, JODOIN, JULIE
Format Patent
LanguageEnglish
French
German
Published 19.11.2014
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular, the present invention relates to a method of regulating the activation of plasminogen comprising contacting a solution of pro-urokinase (uPA) or tissue plasminogen activator (tPA) and plasminogen with melanotransferrin (p97) for a time sufficient to effect regulation thereof.
Bibliography:Application Number: EP20040731567